Pharvaris: Positive Top-line Phase 2 Data for Prophylactic Treatment of HAE Attacks

• Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo
  
• 92.3% reduction in occurrence of moderate and severe attacks
• 92.6% fewer attacks treated with on-demand medication by participants
• Deucrictibant well-tolerated
• Pharvaris to host a conference call today at 8:00 a.m. EST

Pharvaris will host a live conference call and webcast to discuss the CHAPTER-1 study topline data in greater detail at 8:00 a.m. EST today via a live webcast; presentation slides may be accessed on the “Events and Presentations” page of the Pharvaris investor relations website. Participants interested in asking a verbal question during the Q&A may do so in the live conference call. An archived replay will also be available on the website for 90 days following the event.

https://www.globenewswire.com/news-release/2023/12/06/2791612/0/en/Pharvaris-Announces-Positive-Top-line-Phase-2-Data-from-the-CHAPTER-1-Study-of-Deucrictibant-for-the-Prophylactic-Treatment-of-HAE-Attacks.html